Alok Jain

Alok Jain

Auto-generated profile, based on publicly available information

Alok Jain

Advanced BioComputing Lab, Department of Bioengineering and Biotechnology, Birla Institute of Technology Mesra, Ranchi 835215, Jharkhand, India

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2020 in Oncotarget
Verified
Journal Article
Open access
PDF file
PKPrathibha Kirave
Prathibha Kirave
PGPiyush Gondaliya
Piyush Gondaliya
BKBhagyashri Kulkarni
Bhagyashri Kulkarni
RRRakesh Rawal
Rakesh Rawal
RGRachana Garg
Rachana Garg
KKKiran Kalia
Kiran Kalia
Https://doi.org/10.18632/oncotarget.27531 Prathibha Kirave, Piyush Gondaliya, Bhagyashri Kulkarni, Rakesh Rawal, Rachana Garg, Alok Jain, Kiran Kalia

1 June 2019 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
ANAnuradha
Anuradha
SPSagarkumar Patel
Sagarkumar Patel
RPRajkumar Patle
Rajkumar Patle
PPPreethi Parameswaran
Preethi Parameswaran
AJAlok Jain
Alok Jain
ASAmit Shard
Amit Shard

1 January 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GVGargi Nikhil Vaidya
Gargi Nikhil Vaidya
PRPooja Rana
Pooja Rana
AVAshwini Venkatesh
Ashwini Venkatesh
DCDeep Rohan Chatterjee
Deep Rohan Chatterjee
DCDarshan Contractor
Darshan Contractor
DKDinesh Kumar
Dinesh Kumar

20 August 2020 in ACS Applied Bio Materials
Verified
Journal Article
Closed access
RDRudradip Das
Rudradip Das
BGBhavinkumar Gayakvad
Bhavinkumar Gayakvad
SSSuchita Dattatray Shinde
Suchita Dattatray Shinde
JRJyoti Rani
Jyoti Rani
AJAlok Jain
Alok Jain
BSBichismita Sahu
Bichismita Sahu

1 May 2021 in The Review of Diabetic Studies
Verified
Journal Article
Open access
NVNazmina Vhora
Nazmina Vhora
UNUjjal Naskar
Ujjal Naskar
AHAishwarya Hiray
Aishwarya Hiray
AKAbhijeet S. Kate
Abhijeet S. Kate
AJAlok Jain
Alok Jain
BACKGROUND : A higher rate of attenuation of molecules in drug discovery has enabled pharmaceutical companies to enhance the efficiency of their hit identification and lead optimization. Selection and development of appropriate in-vitro and in-vivo strategies may improve this process as primary and secondary screening utilize both strategies. In-vivo approaches are too relentless and expensive for assessing hits. Therefore, it has become indispensable to develop and implement suitable in-vitro screening methods to execute the required activities and meet the respective targets. However, the selection of an appropriate in-vitro assay for specific evaluation of cellular activity is no trivial task. It requires thorough investigation of the various parameters involved. AIM : In this review, we aim to discuss in-vitro assays for type 2 diabetes (T2D), which have been utilized extensively by researchers over the last five years, including target-based, non-target based, low-throughput, and high-throughput screening assays. METHODS : The literature search was conducted using databases including Scifinder, PubMed, ScienceDirect, and Google Scholar to find the significant published articles. DISCUSSION and CONCLUSION : The accuracy and relevance of in-vitro assays have a significant impact on the drug discovery process for T2D, especially in assessing the antidiabetic activity of compounds and identifying the site of effect in high-throughput screening. The report reviews the advantages, limitations, quality parameters, and applications of the probed invitro assays, and compares them with one another to enable the selection of the optimal method for any purpose. The information on these assays will accelerate numerous procedures in the drug development process with consistent quality and accuracy.

8 March 2021 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
GRGourav Rakshit
Gourav Rakshit
PDPankaj Dagur
Pankaj Dagur
SSSwaha Satpathy
Swaha Satpathy
APArjun Patra
Arjun Patra
AJAlok Jain
Alok Jain
Manik GhoshManik Ghosh
Manik Ghosh
Since time immemorial natural products have been a great source of medicine to mankind. The anti-viral activities from several ayurvedic herbal medicines (in the form of crude extract or fraction or isolated compounds) have been established but their effectiveness against coronavirus still needs to be explored. They can provide a rich resource of anti-SARS-CoV-2 drug candidates. In this paper, in-silico techniques have been used to identify the potential lead molecules against SARS-CoV-2. A list of flavonoids having anti-viral activity was prepared and evaluated against the selected target. Rhoifolin, 5,7-dimethoxyflavanone-4′-O-β-d-glucopyranoside, baicalin, astragalin, luteolin, and kaempferol showed good binding affinity and thus these could be promising compounds. In-silico screening such as ADMET prediction has been performed which predicted that the selected flavonoids have good pharmacokinetics and pharmacodynamics properties. Molecular dynamics simulation studies and MM-PBSA binding free energy calculations showed luteolin to be a more effective candidate against viral protein Mpro. The novelty of the approach mainly rests in the identification of potent anti-viral natural molecules from natural products flavonoid group of molecules to be effective against the latest coronavirus infection. Communicated by Ramaswamy H. Sarma